FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy ...Middle East

Wholly owned first-in-class program anticipated to enter clinical trials in first half of 2025 THOUSAND OAKS, Calif., Oct. 30, 2024 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida") today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy )

Also on site :

• Conquering Soccer and Arming Warlords
• Pope Leo XIV marks feast day as Vatican launches campaign to help erase its $57-68 million deficit
• Parvati Shallow Reveals How 'The Traitors' Led to Her Coming Out